Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Indacaterol is a potent, long-acting beta2-adrenergic agonist (LABA) developed primarily for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Chemically known as indacaterol maleate, this molecule features a unique structure that allows for sustained receptor activation. Its molecular formula is C26H35NO4S·C4H4O4, representing the combination of the active base and maleic acid to enhance stability and solubility. The specific CAS number for indacaterol maleate is 908179-85-1, while the free base form carries the CAS number 908179-84-0.
Clinically, indacaterol distinguishes itself through its ultra-long duration of action, providing effective bronchodilation for up to 24 hours following a single daily inhalation. This pharmacokinetic profile offers significant advantages over earlier generation LABAs, which often required twice-daily dosing. By continuously stimulating beta2 receptors in the smooth muscle of the airways, it inhibits the release of inflammatory mediators and prevents bronchoconstriction, thereby improving lung function and reducing the frequency of COPD exacerbations. The drug is marketed under various brand names globally, including Arcapta Neohaler, Onbrez Breezhaler, and Utibron Neohaler, depending on the region and formulation device.
The therapeutic utility of indacaterol extends beyond simple symptom relief; it contributes to improved exercise tolerance and quality of life for patients suffering from moderate to severe COPD. It is typically administered via dry powder inhalers or soft mist inhalers, ensuring precise delivery directly to the lungs with minimal systemic absorption. While generally well-tolerated, common side effects may include nasopharyngitis, headache, and cough, though serious cardiovascular events are rare when used as directed. Indacaterol is not indicated for the reversal of acute bronchospasm but serves as a cornerstone maintenance therapy in modern respiratory care guidelines. Its development marked a significant advancement in respiratory pharmacology, offering patients a simplified once-daily regimen that enhances adherence and clinical outcomes in the management of chronic airway diseases.